摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-甲基-2-哌啶-4-基-1H-苯并咪唑 | 295790-48-6

中文名称
5-甲基-2-哌啶-4-基-1H-苯并咪唑
中文别名
——
英文名称
4-(5-methyl-1H-benzimidazol-2-yl)piperidine
英文别名
5-Methyl-2-piperidin-4-yl-1H-benzoimidazole;6-methyl-2-piperidin-4-yl-1H-benzimidazole
5-甲基-2-哌啶-4-基-1H-苯并咪唑化学式
CAS
295790-48-6
化学式
C13H17N3
mdl
MFCD09027607
分子量
215.298
InChiKey
SGSHCWRNRXJLTC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.461
  • 拓扑面积:
    40.7
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933990090

SDS

SDS:c5005485547b8e09b2012564e8f357f2
查看

反应信息

  • 作为反应物:
    描述:
    5-甲基-2-哌啶-4-基-1H-苯并咪唑 在 sodium azide 、 MP-BH3(CN) 、 zinc dibromide 作用下, 以 为溶剂, 反应 0.33h, 生成 6-Methyl-2-(1-{4-[3-phenyl-5-(1H-tetrazol-5-yl)-pyridin-2-yl]-benzyl}-piperidin-4-yl)-1H-benzoimidazole
    参考文献:
    名称:
    Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
    摘要:
    This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compounds from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1. (C) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.12.062
  • 作为产物:
    参考文献:
    名称:
    Sulfonamide derivatives as 5-HT7 receptor antagonists
    摘要:
    本发明涉及具有5-HT7受体拮抗活性的新型磺酰胺化合物,其制备方法,包含它们的组合物以及它们在中枢神经系统和其他疾病治疗中的用途。其中:Q是苯基或噻吩基;R1是卤素,羟基,C1-6烷基,CF3,OCF3或C1-6烷氧基;m为0、1、2或3;R2是C1-4烷基;X是碳或CH,在X为氮或CH时为单键,在X为碳时为双键;D是单键,C═O,O或CH2,但当X为氮时,D不是氧;P是含1至3个氧、氮和硫的5或6元杂环芳基环,或含1至3个氧、氮和硫的苯并杂环芳基环;R3是C1-6烷基,可选择地被NR4R5,芳基,芳基C1-6烷基,C1-6烷氧基,C1-6烷硫基,氰基,羟基,硝基,卤素,CF3,C2F5,NR4R5,CONR4R5,NR4COR5,S(O)pNR4R5,CHO,OCF3,SCF3,CH2OR6,CO2R6或COR6取代,其中p为0、1或2,R4、R5和R6独立地为氢,C1-6烷基,芳基或芳基C1-6烷基;n为0、1、2或3。
    公开号:
    US06660751B1
点击查看最新优质反应信息

文献信息

  • [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
    申请人:GRUENENTHAL GMBH
    公开号:WO2010099938A1
    公开(公告)日:2010-09-10
    The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).
    本发明涉及磺酰化四氢咯啉吡嗪,其制备方法,含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用(式I)。
  • Combination therapy with CHK1 inhibitors
    申请人:Gesner G. Thomas
    公开号:US20050256157A1
    公开(公告)日:2005-11-17
    Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.
    结构I的化合物及其盐类、互变异构体、立体异构体和混合物可用于抑制受试者中的检查点激酶1,用于诱导细胞周期进展的方法,以及用于增加细胞凋亡的方法。这些化合物可用于制备药物组合物,并且可以与DNA损伤剂联合使用。
  • Inhibition of FGFR3 and treatment of multiple myeloma
    申请人:Cai Shaopei
    公开号:US20050261307A1
    公开(公告)日:2005-11-24
    Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.
    提供了抑制成纤维母细胞生长因子受体3并治疗由纤维母细胞生长因子受体3介导的各种疾病的方法,包括向受试者施用结构I的化合物,其药学上可接受的盐,其互变异构体,或其互变异构体的药学上可接受的盐。具有结构I的化合物具有以下结构,其中具有本文描述的变量。这些化合物可用于制备用于抑制纤维母细胞生长因子受体3和用于治疗由纤维母细胞生长因子受体3介导的疾病,如多发性骨髓瘤的药物。
  • Synthesis and antimicrobial evaluation of substituted benzimidazolyl fluoroquinolones under conventional and microwave irradiation conditions
    作者:Batthini Guruswamy、Ramakrishnan Arul
    DOI:10.1515/hc-2012-0082
    日期:2012.10.1
    were prepared using a conventional methodology and with the help of a microwave irradiation technique. The structures of the synthesized compounds were established on the basis of spectral and analytical data. The antimicrobial activities of newly synthesized compounds were evaluated against a number of microorganisms by using ciprofloxacin as reference. Many of the evaluated compounds exhibit remarkable
    摘要 使用传统方法并借助微波辐射技术制备了新的环丙沙星类似物 3a-i。合成化合物的结构是根据光谱和分析数据确定的。通过使用环丙沙星作为参考,评估了新合成化合物对多种微生物的抗菌活性。许多被评估的化合物对革兰氏阳性菌如金黄色葡萄球菌、链球菌、芽孢杆菌、革兰氏阴性菌如大肠杆菌、肺炎克雷伯菌、铜绿假单胞菌、沙门氏菌、伤寒沙门氏菌和念珠菌具有显着的抗真菌活性。其中,化合物 3a、
  • Sulfonamide derivatives as 5-HT7 receptor antagonists
    申请人:SmithKline Beecham p.l.c.
    公开号:US06660751B1
    公开(公告)日:2003-12-09
    The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1 is halogen, hydroxy, C1-6alkyl, CF3, OCF3 or C1-6alkoxy; m is 0, 1, 2 or 3; R2 is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2 subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3 is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6 or COR6 where p is 0, 1 or 2 and R4, R5 and R6 are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.
    该发明涉及具有5-HT7受体拮抗活性的新型磺胺类化合物,其制备方法,含有它们的组合物以及它们在治疗中枢神经系统和其他疾病中的用途。 其中: Q为苯基或噻吩基; R1为卤素、羟基、C1-6烷基、三氟甲基、OCF3或C1-6烷氧基; m为0、1、2或3; R2为C1-4烷基; X为碳或CH, 当X为氮或CH时,为单键, 当X为碳时,为双键, D为单键、C═O、O或CH2,但当X为氮时,D不是氧; P为含有1至3个氧、氮和硫杂原子的5或6元杂芳基环,或者含有1至3个氧、氮和硫杂原子的苯并杂芳基环; R3为C1-6烷基,可选择地被NR4R5、芳基、芳基C1-6烷基、C1-6烷氧基、C1-6烷基硫基、氰基、羟基、硝基、卤素、三氟甲基、C2F5、NR4R5、CONR4R5、NR4COR5、S(O)pNR4R5、CHO、OCF3、SCF3、CH2OR6、CO2R6或COR6取代,其中p为0、1或2,R4、R5和R6独立地为氢、C1-6烷基、芳基或芳基C1-6烷基; n为0、1、2或3。
查看更多